Literature DB >> 11045651

Rapamycin induces transforming growth factor-beta production by lymphocytes.

I L Dodge1, G Demirci, T B Strom, X C Li.   

Abstract

BACKGROUND: Under certain conditions rapamycin and transforming growth factor- (TGF) beta have similar immunoregulatory effects, suggesting a potential functional link between rapamycin and TGF-beta.
METHODS: Splenic leukocytes were stimulated in vitro with anti-CD3 or with allogeneic cells in vivo in the presence or absence of rapamycin. TGF-beta production by activated lymphocytes was quantitated using ELISA.
RESULTS: Splenic leukocytes from BALB/c mice that were primed with allogeneic cells and conditioned with rapamycin in vivo as well as splenic leukocytes that were treated with rapamycin in vitro produced significantly higher levels of TGF-beta upon anti-CD3 stimulation as compared with untreated controls.
CONCLUSION: Our data suggest that rapamycin can program activated lymphocytes to produce TGF-beta. Thus, the immunosuppressive effects of rapamycin may be partially mediated by TGF-beta.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11045651     DOI: 10.1097/00007890-200010150-00020

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

1.  Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg.

Authors:  Moanaro Biswas; Debalina Sarkar; Sandeep R P Kumar; Sushrusha Nayak; Geoffrey L Rogers; David M Markusic; Gongxian Liao; Cox Terhorst; Roland W Herzog
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

2.  Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction.

Authors:  Josh Levitsky; Lorenzo Gallon; Joshua Miller; Anat R Tambur; Joseph Leventhal; Catherine Flaa; Xuemei Huang; Bara Sarraj; Edward Wang; James M Mathew
Journal:  Transplantation       Date:  2011-01-27       Impact factor: 4.939

3.  Inhibitory effects of belatacept on allospecific regulatory T-cell generation in humans.

Authors:  Josh Levitsky; Joshua Miller; Xuemei Huang; Dhivya Chandrasekaran; Li Chen; James M Mathew
Journal:  Transplantation       Date:  2013-10-27       Impact factor: 4.939

4.  Combined administration of a mutant TGF-beta1/Fc and rapamycin promotes induction of regulatory T cells and islet allograft tolerance.

Authors:  Wensheng Zhang; Dong Zhang; Miaoda Shen; Yun Liu; Yan Tian; Angus W Thomson; W P Andrew Lee; Xin Xiao Zheng
Journal:  J Immunol       Date:  2010-09-15       Impact factor: 5.422

5.  Generation of human regulatory T cells de novo with suppressive function prevent xenogeneic graft versus host disease.

Authors:  Xiaofeng Qian; Ke Wang; Xuehao Wang; Song Guo Zheng; Ling Lu
Journal:  Int Immunopharmacol       Date:  2010-12-13       Impact factor: 4.932

6.  Generation of adaptive regulatory T cells by alloantigen is required for some but not all transplant tolerance protocols.

Authors:  James I Kim; Matthew R O'connor; Patrick E Duff; Gaoping Zhao; Kang Mi Lee; Philip Eliades; Shaoping Deng; Heidi Yeh; Andrew J Caton; James F Markmann
Journal:  Transplantation       Date:  2011-04-15       Impact factor: 4.939

7.  T-cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy.

Authors:  Mercè Brunet; Josep M Campistol; Fritz Diekmann; David Guillen; Olga Millán
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

8.  Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells.

Authors:  W Gao; Y Lu; B El Essawy; M Oukka; V K Kuchroo; T B Strom
Journal:  Am J Transplant       Date:  2007-05-19       Impact factor: 8.086

9.  mTOR signaling inhibition modulates macrophage/microglia-mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia.

Authors:  Luokun Xie; Fen Sun; Jixian Wang; XiaoOu Mao; Lin Xie; Shao-Hua Yang; Dong-Ming Su; James W Simpkins; David A Greenberg; Kunlin Jin
Journal:  J Immunol       Date:  2014-05-14       Impact factor: 5.422

10.  Sirolimus impairs wound healing.

Authors:  Michael Schäffer; Robert Schier; Markus Napirei; Stefan Michalski; Thilo Traska; Richard Viebahn
Journal:  Langenbecks Arch Surg       Date:  2007-03-24       Impact factor: 2.895

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.